Patterson, J
Running distance, food intake and body weight were measured daily before dosing of experimental compounds
Prescription GLP-1 receptor agonists may be indicated for adults with type 2 diabetes not meeting glycemic targets, those with established cardiovascular disease or chronic kidney disease, or individuals with obesity and weight-related complications when lifestyle interventions prove insufficient
Meta-analysis of these eight CVOTs with 60 080 patients included showed that GLP-1 receptor agonists reduce MACE and have a positive impact on chronic kidney disease in patients with T2D ( Dose-dependent effect for oral semaglutide was assessed and proven in Japanese PIONEER 9 trial, where greater reduction of HbA1c and weight loss was achieved with higher dose of oral semaglutide compared to placebo and 0.9 mg liraglutide (46)
Use 0.7 to 1.0 grams of protein per pound of goal body weight as your daily target
The most important factor is consistency and adherence to the prescribed regimen, with timing adjusted to suit individual lifestyle, side effect patterns, and clinical needs